Source link : https://www.newshealth.biz/health-news/fda-expands-approval-of-ribociclib-to-early-breast-cancer/
The FDA on Tuesday approved ribociclib (Kisqali) in combination with endocrine therapy as adjuvant treatment for early high-risk breast cancer. Already approved in the metastatic setting, the CDK4/6 inhibitor is now also indicated for patients with stages II-III disease who have hormone receptor (HR)-positive/HER2-negative tumors and a high risk for recurrence following surgery. The drug […]
Author : News Health
Publish date : 2024-09-17 20:46:21
Copyright for syndicated content belongs to the linked Source.